

Negative Symptoms and Their Associations with Other Clinical Variables and Working Memory Across the Schizophrenia Spectrum and Bipolar Disorder

Marco De Pieri^{1*}, Xaver Berg^{2*}, Foivos Georgiadis², Janis Brakowski², Achim Burrer², Michel Sabe¹, Mariia Kaliuzhna¹, Stefan Vetter², Erich Seifritz², Philipp Homan², Stefan Kaiser¹, Matthias Kirschner^{1,2}

¹Division of Adult Psychiatry, Department of Psychiatry Geneva University Hospitals Geneva, Switzerland

²Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital University of Zurich, Switzerland

³Neuroscience Center Zurich, University of Zurich and Swiss Federal Institute of Technology Zurich, Switzerland

*Both authors contributed equally

Corresponding author: matthias.kirschner@hug.ch, Dr Matthias Kirschner, Division of Adult Psychiatry, Department of Psychiatry Geneva University Hospitals Geneva, Chemin du Petit-Bel-Air CH-1226 Thônex, Switzerland.

ABSTRACT

Negative symptoms (NS) of schizophrenia spectrum disorders (SSD) are also prevalent in bipolar-disorder-I (BD-I) and show associations with impaired working memory (WM). However, empirical work on their relationship to other clinical factors across SSD and BD-I are sparse. Here, we characterized the associations of NS with key clinical variables and WM capacity across a combined sample of SSD and BD. We included 50 outpatients with SSD and 49 with BD-I and assessed NS domains using SANS global scores for avolition-apathy, anhedonia-asociality, alogia and blunted affect. We assessed the transdiagnostic relationship between NS and other clinical variables including positive symptoms, disorganization, depressive symptoms, antipsychotic medication using multiple regressions. The strength of these associations was further determined through dominance analyses. Lastly, we used multiple regression to assess the relationship between NS domains and WM. To assess the generalizability of transdiagnostic associations, analyses were repeated in each diagnostic group separately. Across SSD and BD-I, disorganization was associated with avolition-apathy and anhedonia-asociality and depressive symptoms additionally predicted anhedonia-asociality. Antipsychotic dose was associated with blunted affect while group differences only predicted alogia. Higher avolition-apathy was related to impaired WM transdiagnostically, partially mediated by severity of disorganization, whereas only in BD-I higher anhedonia-asociality was associated with better WM capacity. This study demonstrated transdiagnostic associations of both avolition-apathy and anhedonia-asociality with disorganization, and identified avolition-apathy as potential transdiagnostic predictor of WM impairments. Overall, our findings highlight the importance of understanding the relationship between NS domains and other clinical factors with cognitive function across SSD and BD.

INTRODUCTION

Negative symptoms (NS) are a core feature of schizophrenia spectrum disorders (SSD) and encompass avolition, anhedonia, asociality, alogia and blunted affect¹. These five symptom domains can be classified in two dimensions: the amotivation dimension includes avolition, anhedonia, asociality and the diminished expression dimension includes blunted affect and alogia^{2,3}. Both NS dimensions relate differently to clinical outcomes⁴⁻⁸ and have divergent behavioral and neurobiological substrates^{3,9-14}. Recent psychometric research supports an even more granular differentiation into the five NS domains¹⁵ suggesting for example distinct neural correlates of avolition and anhedonia in individuals with SSD. At the neural level, this is supported to date by few studies that identify neural substrates that are distinct for avolition and anhedonia¹² whereas in most studies neural substrates are associated with both avolition and anhedonia^{11,14,16}.

Though NS have been long viewed as a signature symptom of SSD, distinguishing them from other psychotic manifestations such as disorganization and positive symptoms¹⁷, recent literature suggests NS are also present in other psychiatric conditions¹⁸⁻²⁰. Given the clinical, genetic and biological proximity of SSD and bipolar disorder I (BD-I)²¹⁻²⁵, cross-disorder studies of NS spanning SSD and BD have become increasingly pertinent. Recent studies support such a transdiagnostic construct of NS showing similar levels of avolition and anhedonia but higher levels of blunted affect and alogia in schizophrenia relative to BD-I patients^{20,26,27}.

NS can be further distinguished into primary or secondary NS^{28,29}. The concept of secondary NS originated in the seminal work from Carpenter et al. in the mid-80s³⁰, and its significance in contemporary research and clinical practice has been reiterated by various scholars^{28,29,31}. Primary NS are thought to be intrinsic to the pathological processes underlying schizophrenia and not related to other symptoms or clinical factors. Secondary NS are defined as NS that are related to other clinical factors including positive symptoms, depression,

medications' side effects, social deprivation, and substance abuse^{28–30,32}. In clinical contexts, secondary NS often manifest in various ways: anhedonia may arise from depressive symptoms; avolition can result from pronounced delusions, where delusional beliefs hinder an individual's capacity to engage in social, occupational, and other goal-directed activities; blunted affect might also be a medication side effect. Such secondary NS might be effectively addressed, if the underlying causes are identified and adequately treated. With respect to NS due to positive symptoms this is indirectly supported by acute treatment trial reporting a joint reduction in positive and NS³³. In summary, the differentiation of primary and secondary negative symptoms is difficult, in both clinical and research settings. NS that emerge/alleviate in response to changes in causative factors (e.g., onset/recovery of other symptoms; administration/withdrawal of medication) are more likely secondary, while NS that are long-standing and not fluctuating despite changes in causative factors should be considered as primary^{29,31}.

Working memory (WM) is the function of temporary storage of information and is critical for multiple other processes including language, executive functions, learning and memory³⁴. WM impairments are well documented across all the stages of SSD, from disease onset^{35–37} to the chronic phase³⁸. In addition, poorer education and social achievements of patients with SSD have been attributed to WM impairment³⁹. Similarly, in patients with BD-I, WM is impaired regardless of the phase of the illness⁴⁰, with deficits persisting in the euthymic phase⁴¹ and representing the cognitive deficit more specifically related to functional outcomes^{42–44}.

Several studies indicate a positive association between cognitive dysfunction, including WM, with negative symptom severity^{45–49} and impaired reward-based decision making^{45,50,51}. Moreover, it was proposed that negative symptoms mediate the association between cognitive impairment and functioning in patients with SSD⁵². Recently, attention was given to the transdiagnostic associations between amotivation and impaired WM in both SSD and BD-I⁵³.

The present study addressed two intertwined questions to shed light on the cross-disorder significance of different NS domains. The primary objective of the study was to investigate the transdiagnostic relationship between NS domains across SSD and BD and potential underlying sources of secondary NS. The secondary objective of the study was to study the relationship between NS domains and WM function across SSD and BD individuals. Besides these two main objectives focused on a transdiagnostic perspective, we also established an exploratory analysis to test whether the transdiagnostic findings can be confirmed in both SSD and BD separately. Based on previous reports^{26,27} we hypothesized that levels of avolition and anhedonia would be comparable in SSD and BD-I, while blunted affect and alogia would be stronger in SSD compared to BD-I. For investigation of WM and negative symptoms, we hypothesized that reduced WM capacities would be related to higher levels of avolition/apathy, based on the existing literature⁴⁵⁻⁴⁹.

METHODS

Participants

Demographic and clinical data of outpatient individuals with SSD and with BD-I from UCLA consortium for neuropsychiatric phenomics (CNP) were downloaded from the public database OpenfMRI (<https://openfMRI.org/dataset/ds000030/>). In total this database includes a sample size of 50 individuals with SSD and 49 individuals with BD-I, which is line with previous reports investigating negative symptoms across SSD and BD-I^{26,27}. The current sample of the CNP was part of a larger multimodal imaging cohort including data from healthy controls and individuals with ADHD, which are not subject to this study. For more details of the CNP cohort see⁵⁴. All the available patients satisfying inclusion and exclusion criteria were recruited, via outreach to local clinics and via online portals. Inclusion criteria were: Age between 21 and 50 years; primary language either English or Spanish; a minimum of 8 years of formal education; no significant medical illness; demonstrated clinical stability allowing to complete the clinical

assessment; negative drug test (urine sample tested for cocaine, methamphetamine, morphine, tetrahydrocannabinol, benzodiazepines).

Clinical assessment

Experienced senior psychiatrists realized a comprehensive clinical assessment was applied across both groups to assess NS and potential sources of NS including positive symptoms, disorganization, depression, and current antipsychotic as well as current mood stabilizing medications. The Scale for the Assessment of Negative Symptoms (SANS) was used to assess the four NS domains blunted affect, alogia, avolition-apathy, anhedonia-asociality. Following previous work from Strauss and Cohen, the global rating scores were used to measure severity of each NS domains²⁰. In addition, the motivation and pleasure dimensions were defined by combining the avolition-apathy and anhedonia-asociality domains, and the diminished expression dimension by combining the blunted affect and alogia domains, respectively^{5,26}. Positive symptoms were assessed using the Scale for the Assessment of Positive Symptoms (SAPS). Following the work of Peralta et al⁵⁵ and of Tibber et al¹⁷, global scores of the SAPS domains delusions, hallucinations, bizarre behavior and positive formal thought disorder were used to define two dimensions: the positive symptom dimension includes the delusion and hallucination global scores; the disorganization dimension comprises the bizarre behavior and positive formal thought disorder global scores. To assess depressive symptoms the 21-item version of the Hamilton Scale for Depression (HAMD-21) was used. Lastly, daily antipsychotic doses and use of mood stabilizers were determined. Individual doses of antipsychotics were converted in oral risperidone equivalent doses using the defined daily doses (DDD) method⁵⁶.

Working memory

WM was assessed using total raw scores from symbol span and visual reproduction (both from the Wechsler Memory Scale), as well as total raw scores from digit span and letter number

sequencing (both from Wechsler Adult Intelligence Scale IV). The total raw scores were standardized using z transformation and a composite WM sum score was calculated by combining all four independent z scores. To account for the influence of age on working memory, as previously reported in SSD⁵⁷ and BD-I⁵⁸, age was regressed-out from the composite WM score and the age-corrected residuals were used for all subsequent analysis.

Data analysis

All analyses were performed using SPSS (version 27.00, SPSS Inc.) and graphics were created with ggplot2 and reshape packages in R (© 2009-2021 RStudio, PBC; 2021.09.0 Build 351).

Group comparison of clinical variables between SSD and BD-I

Prior to our transdiagnostic analyses, we first applied group comparisons of all clinical variables including positive symptoms, negative symptoms, disorganization, depressive symptoms, daily antipsychotic dose, and use of mood stabilizer. These variables were examined using analysis of covariance (ANCOVA).

Associations between negative symptoms and other clinical factors

We applied a transdiagnostic approach to examine associations between each NS domain and potential sources of NS across SSD and BD. For each NS domains, we performed a separate multiple linear regression analysis including group, positive symptoms, disorganization, depression, and RSP-eq dose as covariates. Given the body of evidence indicating the possible influence of age^{59–64} and sex^{64–68} on NS, their potential role as confounders was assessed using The Spearman correlation and the Wilcoxon rank sum test for age and sex, respectively. Since these two variables were not significantly related to negative symptoms (**Table S3** and **S4**) in both the transdiagnostic group and in the SSD and BD subgroups, they were not included in the multivariate analysis described below. However, alternative multivariate models including age

and sex were also realized to confirm that age and sex did not influence the main findings. We next applied dominance analyses to further contextualize the relative importance of each clinical factor in explaining the NS domains⁶⁹. Dominance analysis is a statistical method designed to establish the relative importance of predictor variables in comparison to all other predictors (in this instance, potential sources of secondary NS) within a statistical model. This method facilitates ranking and scaling predictor variables in multiple regression analyses qualitatively via pairwise comparison. This strategy enables the identification of dominant variables in terms of their efficacy in predicting the variance of the dependent variable in the presence of other variables. **Figure 2** presents a visualization of the relative importance scores for each predictor variable, displayed as a heatmap. Darker shades signify reduced dominance for the respective predictor variable⁶⁹.

To facilitate comparisons with studies employing the two-factor model of NS, all analyses were repeated by executing the multiple linear regression analyses using the two NS dimensions. Finally, to control that none of the transdiagnostic findings was driven by either SSD or BD-I, regression analyses were repeated within each subgroup separately.

Associations between working memory and negative symptoms

In alignment with the transdiagnostic approach mentioned above, the relationships between WM and NS domains were first assessed across both groups. Considering previous findings of a sex influence on WM in both SSD and BD-I⁷⁰⁻⁷⁴, sex was evaluated as a potential confounder in our cohort, but no significant association emerged. Accordingly, sex was not included in the linear regression model for our main results. However, for further precision, a secondary analysis was also realized, including sex in the same regression model. Since age had a significant effect on WM performance in our cohort (as described above), age was first regressed out from the WM composite score. To this end a multiple linear regression model were fitted, using the four NS domains, potential secondary sources of NS, and diagnostic group

as independent (predictor) variables. Finally, to assess potential group-specific associations between WM and NS domains, explorative regression analyses were performed in each subgroup separately. We corrected the main transdiagnostic analyses including the four NS domains regression analysis as well as the WM regression analysis (n=5 tests) for multiple comparison using a False Discovery Rate (FDR) of $q < 0.05$ (pFDR < 0.05) based on the Benjamini-Hochberg method ⁷⁵.

RESULTS

Demographic and clinical data

Fifty patients with SSD and 49 patients with BD-I were included in the study; All participants were outpatients and diagnoses were confirmed following DSM-IV criteria using a semi-structured assessment with Structured Clinical Interview (SCID) for the DSM-IV (**Table S1**). Demographic and clinical data are summarized in **Table 1**. We observed no group difference in age ($F = 0.128$, $p = 0.880$), but the proportion of male subjects in the SSD group compared to the BD-I group was higher (SSD (76%) vs BD-I (57%), $\chi^2 = 11.00$; $p < 0.001$). Both groups exhibited mild to moderate levels of SANS avolition-apathy and SANS anhedonia-asociality and subclinical levels of SANS blunted affect and SANS alogia, with very low levels of alogia in BD-I.

With respect to other symptom dimensions, subjects with SSD had higher SAPS positive symptoms dimension scores ($F = 44.443$, $p = 0.000$) than subjects with BD-I, while subjects with BD-I had higher HAMD-21 scores ($F = 3.765$, $p = 0.027$). In contrast, SAPS disorganization dimension scores did not differ between groups ($F = 2.911$, $p = 0.059$). Comparing medication dose, we found no group differences in risperidone equivalent doses ($F = 1.41$, $p = 0.25$), while mood stabilizers were more often prescribed in the BD-I group ($\chi^2 = 15.69$, $p < 0.001$).

Potential clinical sources of negative symptoms

Multiple linear regression models were used to contextualize potential sources for negative symptoms for each NS domain across SSD and BD-I. Both higher SANS avolition-apathy ($\beta = 0.25$, $p < 0.001$), and higher SANS anhedonia-asociality ($\beta = 0.20$, $p < 0.005$) were significantly associated with SAPS disorganization dimension, while depressive symptoms were additionally related to SANS anhedonia-asociality ($\beta = 0.05$, $p < 0.001$). Risperidone equivalent dose was associated with higher SANS blunted affect ($\beta = 0.03$; $p < 0.05$), but this result was not significant after correction for multiple testing. SANS alogia showed no relationship with any of the potential sources for secondary NS. Positive symptoms were assessed as potential secondary sources, but no significant associations between the SAPS positive dimension and any NS domain were observed across both groups (**Figure 1, Table 2**). Notably, significant group differences were only observed in alogia ($\beta = -0.74$; $p < 0.05$) with more severe alogia in SSD compared to BD-I. To further quantify the variance of NS explained through each clinical factor related to NS, we performed separate dominance analyses for each NS domain. The generalized relative importance values are shown in **Figure 2**, indicating how the underlying sources of secondary NS contribute to the measured SANS domain scores. Overall, the dominance analyses confirm the findings of the multiple linear regression models, highlighting the importance of disorganization in predicting SANS avolition-apathy and anhedonia-asociality.

Using the SANS, amotivation and the diminished expression dimensions largely replicated the results from the four SANS domain scores. SAPS disorganization scores and depressive symptoms were associated with the SANS amotivation dimension ($\beta = 0.47$, $p < 0.001$ and $\beta = 0.07$; $p < 0.05$, respectively). In line with the observed group differences in SANS alogia, the SANS diminished expression was different in SSD and BD-I ($\beta = -1.27$, $p < 0.05$; SSD>BD-I) (**Table 3**). Finally, analyses for SSD and BD-I separately, largely confirmed the cross-disorder results, albeit with smaller effect sizes (**Table S5**). Taken together across SSD

and BD-I, disorganization, depressive symptoms and antipsychotic medication were significantly associated with NS domains, while group differences only predicted alogia. Finally, repeating the analyses including age and sex in the regression model, did not significantly change the results (**Supplementary Table S6**).




Figure 1. Associations between Negative symptoms and their potential sources. Significant beta values from linear multivariate regressions shown in Table 2 are presented. * $p < 0.05$; ** $p < 0.005$; *** $p < 0.001$




Figure 2. Dominance analysis of potential secondary sources of the negative symptom domains. Visualization of relative importance scores of causes of secondary negative symptoms on a standardized scale from 0 (no importance) to 1 (high importance) as a heatmap. Brighter colors are corresponding to higher percentage of relative importance.

Associations of working memory and clinical variables

In a next step, we sought to examine the relationship between NS and WM across SSD and BD-I and in each group separately (**Table 4**). In our transdiagnostic model, higher WM scores were explained by group ($\beta = 2.77$, $p < 0.005$) with better WM in BD-I than SSD. Furthermore, across both groups, a higher SANS avolition-apathy scores were associated with lower WM scores ($\beta = -0.74$, $p < 0.005$). None of the other symptom dimensions or medication dose were related to WM. Examining the relationship between NS and WM in SSD and BD-I separately, the negative effect of SANS avolition-apathy was observed in both disorders although with higher effect size in individuals with BD-I ($\beta = -1.07$, $p < 0.001$) compared to individuals with SSD ($\beta = -0.58$, $p > 0.05$). In addition to the negative relationship between higher SANS avolition-apathy scores and WM, subjects with BD-I showed an inverse positive association between higher SANS anhedonia-asociality and WM ($\beta = 1.32$, $p < 0.005$). In other words, BD-I subjects with higher SANS avolition-apathy had reduced WM scores, while those with higher SANS anhedonia-asociality had higher WM scores. In sum, across both groups more severe SANS avolition-apathy scores and group differences (SSD<BD-I) predicted lower WM, while in BD-I only, higher SANS anhedonia-asociality showed an inverse relationship with WM (i.e. higher scores). **Supplementary table S7** shows the results obtained with a different regression model including sex among the predictive variables, which led to no relevant differences compared to the results displayed in this paragraph.

Mediation analysis

Poor WM is associated with both disorganization^{76,77} and avolition-apathy^{4,19} in patients with SSD. In the given sample, higher disorganization correlated with higher avolition-apathy and higher avolition-apathy corresponded to lower WM. Therefore, we performed a mediation analysis to examine whether disorganization influences the effect of WM on avolition-apathy (see Figure 3). Regressing disorganization on WM showed a trend effect of higher WM being associated with lower disorganization scores (a). Regressing disorganization on avolition-apathy revealed a highly significant positive association (b). When regressing WM on avolition-apathy (c), a negative effect was observed, with lower WM correlating with higher avolition-apathy. Adding disorganization as a mediator (c') reduced the significant association between WM and avolition-apathy (c) and showed a significant mediation effect of disorganization on the relationship between WM and avolition-apathy (a*b). Collectively, this analysis suggests that WM has a significant direct effect on avolition-apathy and an additional indirect effect mediated by disorganization across SSD and BD.




Figure 3. Mediation analysis of working memory (WM), disorganization and avolition-apathy.

DISCUSSION

In the present study we applied a transdiagnostic approach to characterize NS domains and their relationships with potential sources of secondary NS across a combined sample of SSD and BD-I. We further evaluated the transdiagnostic association between distinct NS domains and WM capacity. Across individuals with SSD and BD-I, disorganization was associated with avolition-apathy and anhedonia-asociality; depression additionally predicted anhedonia-asociality. In addition, a higher antipsychotic dose was associated with blunted affect. Among all four NS domains only alogia was better predicted by disease categories and not by transdiagnostic clinical dimensions. Avolition-apathy was associated with a reduced WM performance transdiagnostically, while only in the BD-I group higher anhedonia-asociality was associated with better WM. Collectively, these findings provide evidence for associations between NS and disorganization and reveal differential effects of avolition-apathy and anhedonia-asociality on WM in SSD and BD-I.

Over the last years NS have been increasingly recognized as a transdiagnostic construct²⁰, although if, to our knowledge, only few studies have directly compared NS between SSD and BD-I. With respect to the different NS domains, similar levels of avolition and anhedonia have been reported for SSD and BD-I^{26,27}. In contrast, alogia^{26,27} and blunted affect²⁷ differed between both groups with significantly more severe scores in SSD compared to BD-I. Together with these reports, the present findings suggest that avolition and anhedonia are transdiagnostic domains across SSD and BD-I. The diminished expression dimension and in particular the severity of alogia, however, seems to be more strongly differentiated by disease category. Secondary NS are frequently observed in clinical routine; however, empirical studies examining potential underlying sources of secondary NS remain relatively scarce. In the present study higher disorganization was associated with higher avolition-apathy as well as anhedonia-asociality across both disorders and confirmed in each disorder separately. Disorganization has

been conceptualized as one core dimension⁷⁸ along with positive symptoms and NS, which has been consistently confirmed in SSD^{17,55} and across the SSD-BD spectrum²⁵. However, the relation between disorganization and NS has not been receiving much attention. The present findings suggest that disorganization might be a source of secondary avolition-apathy/anhedonia-asociality in patients of the SSD-BD spectrum. One clinical explanation for this association might be that disorganization directly affects the patient's ability to plan and engage in activities and social interaction. In addition, the relationship between disorganization and NS could be of direct clinical interest. In fact, preliminary evidences exist that cariprazine, a 3rd generation antipsychotic drug, could improve NS and additionally disorganization in SSD patients⁷⁹. Hence, secondary avolition-apathy and anhedonia-asociality due to disorganization might partially respond to a treatment with a 3rd generation antipsychotic like cariprazine. It is important to note here that it is also possible that there is no causal relationship between disorganization and NS. Thus, the potential shared treatment effect of cariprazine may be the result of a common underlying mechanism that is targeted by this drug and improves both symptoms independently.

Anhedonia-asociality was additionally related to depressive symptoms across both groups, which is in line with anhedonia as shared feature of depressive symptoms and NS in SSD and BD-I^{26,80,81}. With respect to medication effects, higher daily antipsychotic doses were associated with blunted affect across both disorders. The association, however, was mainly driven by the BD-I group, although medication dose did not differ between BD-I and SSD patients. One previous study reported a similar relationship in BD-I patients but not SSD patients²⁷, raising the question whether BD-I patients are more sensitive to medication-induced affective flattening compared to SSD patients. Extrapyramidal side effects are often suggested as cause of diminished expressivity⁸², although other mechanism might contribute to this relationship. Collectively, these findings show that antipsychotic medication relates to even mild to moderate blunted affect that could potentially be ameliorated with precise drug

monitoring. Of all four NS domains tested in this study, only alogia was predicted by diagnostic category showing significant higher scores in SSD compared to BD-I patients. In addition, alogia was not related to any potential secondary sources, thus suggesting that alogia was a primary NS in this cross-disorder sample. This observation raises the question whether some NS domains are more likely to be secondary due to other clinical factors, while others such as alogia are more likely primary NS.

Neurocognitive deficits are common in psychotic disorders⁸³ and in particular WM capacity is typically impaired in both, patients with SSD or BD-I⁸⁴. Impaired WM has been further related to NS⁵² as well as disorganization^{76,77} in patients with SSD, but not in BD-I patients.

We observed that across SSD and BD-I patients, lower WM was associated with higher avolition-apathy scores suggesting a direct effect of WM on avolition-apathy. Disorganization partly mediated the effect of WM on avolition-apathy, pointing to an additional indirect effect of WM on avolition-apathy. The negative effect of primary avolition-apathy on WM has been consistently observed in different stages of SSD^{4,19,53,85}. Our findings extend these reports by showing that avolition-apathy, associated with disorganization, relates to more severe WM deficits across SSD and BD-I patients. Of note, the relationship between higher avolition-apathy and lower WM performance was more pronounced in BD-I confirming that this result is not purely driven by the SSD group. These results further provide evidence for a transdiagnostic link between WM and higher avolition-apathy scores, which is shared across the SSD-BD spectrum.

In contrast to this transdiagnostic relationship, we observed an inverse association of higher anhedonia-asociality with better WM in BD-I patients only. Anhedonia-asociality was also associated with depressive symptoms in both diagnostic groups. Therefore, one interpretation is that those BD-I patients with subclinical affective symptoms showed overall better WM performance compared to those with less affective symptoms. In addition, this observation was specific for BD-I patients and could potentially reflect the overall better neurocognition seen in

BD-I compared to SSD. This interpretation would be in line with a general model of cognitive functioning across the schizophrenia-bipolar spectrum showing that patients with more affective symptoms have overall better cognitive functioning compared to patients with primary and more enduring psychotic symptoms⁸⁶.

Limitations

There are several limitations to our study. First, the SANS was used to assess NS. SANS is a first-generation questionnaire for the assessment of NS and newer scales such as the Brief Negative Symptom Scale or the Clinical Assessment Interview for Negative Symptoms are available. However, according to the EPA guidelines, the use of the SANS is still viable for research and clinical practice. Furthermore, as proposed in the EPA guidelines, specific items which do not represent NS (like inappropriate affect and inattention) were not used in this study³². In addition, the SANS is a widely used instrument in clinical routine and a significant number of previous NS studies have used this scale allowing comparability of the present work with previous findings and facilitates transfer into clinical practice. Second, while this study addressed the main clinical factors contributing to secondary NS, it did not investigate other potential secondary sources such as environmental, psychological, and biological factors. Moreover, the dataset lacked detailed information regarding the number and frequency of psychotic episodes in the BD-I group. Understanding how the frequency of psychotic episodes might contribute to NS and neurocognitive deficits in BD-I patients could be a relevant avenue for future research. The cross-sectional study design with no follow-up visits examining changes of symptomatology over time does not allow a clear differentiation of primary and secondary NS. Future longitudinal studies will be necessary to further evaluate the role of primary and secondary NS on clinical outcome and function. Extrapyramidal side effects of antipsychotic medications are recognized as a cause of diminished expressivity, independent from efficacy and dosage of these medications⁸⁷. Data on extrapyramidal symptoms were not

available in our dataset, hindering their inclusion in the multivariate analysis. As a consequence, though antipsychotic medication dose was included in the analysis potential associations with extrapyramidal symptoms could not be fully excluded. The total score of the Hamilton Depression Scale does not fully disentangle depression from negative symptoms and could explain at least in part the observed overlap with anhedonia-asociality assessed with the SANS. Our cohort was not replicating age and sex related differences in negative symptoms and sex differences in working memory, as known from the existing literature. The association of age with negative symptoms⁶⁴ remains controversial. Some studies found no association with age or stability of negative symptoms over time^{59,60,88}, others showed that NS were differently related to either older age⁸⁹ or younger age⁶³. In addition, longitudinal studies provided evidence of different NS trajectories with persistence in over 50%, thus suggesting that in some individuals NS might decline while in other they might persist or re-occur⁵⁹. With respect to the age range, studies who directly addressed the relationship between age and NS included samples with larger age range^{63,88,89}. In contrast, the relative narrower age range (35.9 ± 8.9 ; 21-50) in the present study might be a potential limitation to identify this association. There is consistent evidence that NS are known to be more severe in males⁶⁴⁻⁶⁸. Studying sex differences in NS was not an objective of the present study, and therefore the study cohort was not optimized for such an analysis. Therefore, the unequal sex distribution in the present cohort might be the lack of relationship between sex and NS. Sex differences in working memory are reported in previous research, with men being more impaired than female⁷⁰⁻⁷². However, the effect size of the difference was small in these studies, and large sample sizes and a design aimed to evaluate the sex influence on working memory were necessary for a positive result to emerge. In addition, no significant differences were found in other investigations⁹⁰⁻⁹², or an inverse relationship in both SSD⁷³ and BD-I⁷⁴.

CONCLUSIONS

Our findings confirm that NS are prevalent in outpatients with SSD and BD, highlighting the significant role of disorganization as a possible underlying source of avolition and anhedonia. The relationship between avolition-apathy and impaired WM suggests the presence of shared symptom-cognition relationships across SSD and BD-I. Collectively, these findings enhance our understanding of NS and their relationship to other clinical factors and cognitive impairments across the schizophrenia-bipolar spectrum. More broadly these findings might help to advance the development of targeted treatment and preventive measures for NS across SSD and BD.

ACKNOWLEDGEMENTS

All data used in this study were derived from the UCLA CNP cohort. Data can be download from the publicly available database OpenfMRI (<https://openfmri.org/dataset/ds000030/>).

CONFLICT OF INTERESTS

The authors declare that they have no conflicts of interest related to this study.

REFERENCES

1. Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICES Consensus Statement on Negative Symptoms. *Schizophr Bull.* 2006;32(2):214-219. doi:10.1093/schbul/sbj053
2. Blanchard JJ, Cohen AS. The Structure of Negative Symptoms Within Schizophrenia: Implications for Assessment. *Schizophr Bull.* 2006;32(2):238-245. doi:10.1093/schbul/sbj013
3. Bègue I, Kaiser S, Kirschner M. Pathophysiology of negative symptom dimensions of schizophrenia – Current developments and implications for treatment. *Neurosci Biobehav Rev.* 2020;116:74-88. doi:10.1016/j.neubiorev.2020.06.004
4. Faerden A, Vaskinn A, Finset A, et al. Apathy is associated with executive functioning in first episode psychosis. *BMC Psychiatry.* 2009;9(1):1. doi:10.1186/1471-244X-9-1
5. Strauss GP, Horan WP, Kirkpatrick B, et al. Deconstructing negative symptoms of schizophrenia: Avolition–apathy and diminished expression clusters predict clinical presentation and functional outcome. *J Psychiatr Res.* 2013;47(6):783-790. doi:10.1016/j.jpsychires.2013.01.015
6. Mantovani LM, Ferretjans R, Marçal IM, Oliveira AM, Guimarães FC, Salgado JV. Family burden in schizophrenia: the influence of age of onset and negative symptoms. *Trends Psychiatry Psychother.* 2016;38(2):96-99. doi:10.1590/2237-6089-2015-0082
7. Galderisi S, Bucci P, Mucci A, et al. Categorical and dimensional approaches to negative symptoms of schizophrenia: Focus on long-term stability and functional outcome. *Schizophr Res.* 2013;147(1):157-162. doi:10.1016/j.schres.2013.03.020
8. Galderisi S, Rossi A, Rocca P, et al. The influence of illness-related variables, personal resources and context-related factors on real-life functioning of people with schizophrenia. *World Psychiatry.* 2014;13(3):275-287. doi:10.1002/wps.20167
9. Galderisi S, Mucci A, Buchanan RW, Arango C. Negative symptoms of schizophrenia: new developments and unanswered research questions. *Lancet Psychiatry.* 2018;5(8):664-677. doi:10.1016/S2215-0366(18)30050-6
10. Hartmann MN, Hager OM, Reimann A V., et al. Apathy But Not Diminished Expression in Schizophrenia Is Associated With Discounting of Monetary Rewards by Physical Effort. *Schizophr Bull.* 2015;41(2):503-512. doi:10.1093/schbul/sbu102
11. Kirschner M, Hager OM, Bischof M, et al. Ventral striatal hypoactivation is associated with apathy but not diminished expression in patients with schizophrenia. *Journal of Psychiatry and Neuroscience.* 2016;41(3):152-161. doi:10.1503/jpn.140383

12. Mucci A, Dima D, Soricelli A, et al. Is avolition in schizophrenia associated with a deficit of dorsal caudate activity? A functional magnetic resonance imaging study during reward anticipation and feedback. *Psychol Med.* 2015;45(8):1765-1778. doi:10.1017/S0033291714002943
13. Stepien M, Manoliu A, Kubli R, et al. Investigating the association of ventral and dorsal striatal dysfunction during reward anticipation with negative symptoms in patients with schizophrenia and healthy individuals. *PLoS One.* 2018;13(6):e0198215. doi:10.1371/journal.pone.0198215
14. Wolf DH, Satterthwaite TD, Kantrowitz JJ, et al. Amotivation in Schizophrenia: Integrated Assessment With Behavioral, Clinical, and Imaging Measures. *Schizophr Bull.* 2014;40(6):1328-1337. doi:10.1093/schbul/sbu026
15. Strauss GP, Nuñez A, Ahmed AO, et al. The Latent Structure of Negative Symptoms in Schizophrenia. *JAMA Psychiatry.* 2018;75(12):1271. doi:10.1001/jamapsychiatry.2018.2475
16. Kaliuzhna M, Kirschner M, Carruzzo F, et al. How far to go in deconstructing negative symptoms? Behavioural and neural level evidence for the amotivation domain. *Schizophr Res.* 2021;236:41-47. doi:10.1016/j.schres.2021.08.007
17. Tibber MS, Kirkbride JB, Joyce EM, et al. The component structure of the scales for the assessment of positive and negative symptoms in first-episode psychosis and its dependence on variations in analytic methods. *Psychiatry Res.* 2018;270:869-879. doi:10.1016/j.psychres.2018.10.046
18. Kaiser S, Heekeren K, Simon JJ. The Negative Symptoms of Schizophrenia: Category or Continuum? *Psychopathology.* 2011;44(6):345-353. doi:10.1159/000325912
19. Foussias G, Siddiqui I, Fervaha G, et al. Motivated to do well: An examination of the relationships between motivation, effort, and cognitive performance in schizophrenia. *Schizophr Res.* 2015;166(1-3):276-282. doi:10.1016/j.schres.2015.05.019
20. Strauss GP, Cohen AS. A Transdiagnostic Review of Negative Symptom Phenomenology and Etiology. *Schizophr Bull.* 2017;43(4):712-719. doi:10.1093/schbul/sbx066
21. Anttila V, Bulik-Sullivan B, Finucane HK, et al. Analysis of shared heritability in common disorders of the brain. *Science (1979).* 2018;360(6395). doi:10.1126/science.aap8757

22. Cardno AG, Owen MJ. Genetic Relationships Between Schizophrenia, Bipolar Disorder, and Schizoaffective Disorder. *Schizophr Bull.* 2014;40(3):504-515. doi:10.1093/schbul/sbu016
23. Lee PH, Anttila V, Won H, et al. Genomic Relationships, Novel Loci, and Pleiotropic Mechanisms across Eight Psychiatric Disorders. *Cell.* 2019;179(7):1469-1482.e11. doi:10.1016/j.cell.2019.11.020
24. Patel Y, Parker N, Shin J, et al. Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. *JAMA Psychiatry.* 2021;78(1):47. doi:10.1001/jamapsychiatry.2020.2694
25. Reininghaus U, Böhnke JR, Chavez-Baldini U, et al. Transdiagnostic dimensions of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). *World Psychiatry.* 2019;18(1):67-76. doi:10.1002/wps.20607
26. Kirschner M, Cathomas F, Manoliu A, et al. Shared and dissociable features of apathy and reward system dysfunction in bipolar I disorder and schizophrenia. *Psychol Med.* 2020;50(6):936-947. doi:10.1017/S0033291719000801
27. Strauss GP, Vertinski M, Vogel SJ, Ringdahl EN, Allen DN. Negative symptoms in bipolar disorder and schizophrenia: A psychometric evaluation of the brief negative symptom scale across diagnostic categories. *Schizophr Res.* 2016;170(2-3):285-289. doi:10.1016/j.schres.2015.12.014
28. Kirkpatrick B. Developing Concepts in Negative Symptoms. *J Clin Psychiatry.* 2014;75(suppl 1):3-7. doi:10.4088/JCP.13049su1c.01
29. Kirschner M, Aleman A, Kaiser S. Secondary negative symptoms — A review of mechanisms, assessment and treatment. *Schizophr Res.* 2017;186:29-38. doi:10.1016/j.schres.2016.05.003
30. Carpenter WT, Heinrichs DW, Alphas LD. Treatment of Negative Symptoms. *Schizophr Bull.* 1985;11(3):440-452. doi:10.1093/schbul/11.3.440
31. Mosolov SN, Yaltonskaya PA. Primary and Secondary Negative Symptoms in Schizophrenia. *Front Psychiatry.* 2022;12. doi:10.3389/fpsy.2021.766692
32. Galderisi S, Mucci A, Dollfus S, et al. EPA guidance on assessment of negative symptoms in schizophrenia. *European Psychiatry.* 2021;64(1):e23. doi:10.1192/j.eurpsy.2021.11
33. Huhn M, Nikolakopoulou A, Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-

- episode schizophrenia: a systematic review and network meta-analysis. *The Lancet*. 2019;394(10202):939-951. doi:10.1016/S0140-6736(19)31135-3
34. Baddeley AD, Hitch GJ, Allen RJ. From short-term store to multicomponent working memory: The role of the modal model. *Mem Cognit*. 2019;47(4):575-588. doi:10.3758/s13421-018-0878-5
35. Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone S V, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. *Neuropsychology*. 2009;23(3):315-336. doi:10.1037/a0014708
36. White T, Schmidt M, Karatekin C. Verbal and visuospatial working memory development and deficits in children and adolescents with schizophrenia. *Early Interv Psychiatry*. 2010;4(4):305-313. doi:10.1111/j.1751-7893.2010.00204.x
37. Fusar-Poli P, Deste G, Smieskova R, et al. Cognitive functioning in prodromal psychosis: a meta-analysis. *Arch Gen Psychiatry*. 2012;69(6):562-571. doi:10.1001/archgenpsychiatry.2011.1592
38. Ho BC, Wassink TH, O'Leary DS, Sheffield VC, Andreasen NC. Catechol-O-methyl transferase Val158Met gene polymorphism in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow. *Mol Psychiatry*. 2005;10(3):287-298. doi:10.1038/sj.mp.4001616
39. Zhou J, Li J, Zhao Q, Ou P, Zhao W. Working memory deficits in children with schizophrenia and its mechanism, susceptibility genes, and improvement: A literature review. *Front Psychiatry*. 2022;13. doi:10.3389/fpsy.2022.899344
40. Soraggi-Frez C, Santos FH, Albuquerque PB, Malloy-Diniz LF. Disentangling Working Memory Functioning in Mood States of Bipolar Disorder: A Systematic Review. *Front Psychol*. 2017;8. doi:10.3389/fpsyg.2017.00574
41. Bourne C, Aydemir Ö, Balanzá-Martínez V, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. *Acta Psychiatr Scand*. 2013;128(3):149-162. doi:10.1111/acps.12133
42. Depp CA, Mausbach BT, Harmell AL, et al. Meta-analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. *Bipolar Disord*. 2012;14(3):217-226. doi:10.1111/j.1399-5618.2012.01011.x
43. Wingo AP, Harvey PD, Baldessarini RJ. Neurocognitive impairment in bipolar disorder patients: functional implications. *Bipolar Disord*. 2009;11(2):113-125. doi:10.1111/j.1399-5618.2009.00665.x

44. Coppola F, Courtet P, Olié E. Profil neuropsychologique et mémoire de travail dans le trouble bipolaire. *The Canadian Journal of Psychiatry*. 2018;63(5):314-321.
doi:10.1177/0706743717744777
45. O’Leary DS, Flaum M, Kesler ML, Flashman LA, Arndt S, Andreasen NC. Cognitive Correlates of the Negative, Disorganized, and Psychotic Symptom Dimensions of Schizophrenia. *J Neuropsychiatry Clin Neurosci*. 2000;12(1):4-15.
doi:10.1176/jnp.12.1.4
46. Heydebrand G. Correlates of cognitive deficits in first episode schizophrenia. *Schizophr Res*. 2004;68(1):1-9. doi:10.1016/S0920-9964(03)00097-5
47. Melillo A, Caporusso E, Giordano GM, et al. Correlations between Negative Symptoms and Cognitive Deficits in Individuals at First Psychotic Episode or at High Risk of Psychosis: A Systematic Review. *J Clin Med*. 2023;12(22):7095.
doi:10.3390/jcm12227095
48. Mørch-Johnsen L, Smelror RE, Andreou D, et al. Negative Symptom Domains Are Associated With Verbal Learning in Adolescents With Early Onset Psychosis. *Front Psychiatry*. 2022;12. doi:10.3389/fpsy.2021.825681
49. Huang M, Huang Y, Yu L, et al. Relationship between negative symptoms and neurocognitive functions in adolescent and adult patients with first-episode schizophrenia. *BMC Psychiatry*. 2016;16(1):344. doi:10.1186/s12888-016-1052-x
50. Fervaha G, Graff-Guerrero A, Zakzanis KK, Foussias G, Agid O, Remington G. Incentive motivation deficits in schizophrenia reflect effort computation impairments during cost-benefit decision-making. *J Psychiatr Res*. 2013;47(11):1590-1596.
doi:10.1016/j.jpsychires.2013.08.003
51. Cooper JA, Barch DM, Reddy LF, Horan WP, Green MF, Treadway MT. Effortful goal-directed behavior in schizophrenia: Computational subtypes and associations with cognition. *J Abnorm Psychol*. 2019;128(7):710-722. doi:10.1037/abn0000443
52. Ventura J, Helleman GS, Thames AD, Koellner V, Nuechterlein KH. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: A meta-analysis. *Schizophr Res*. 2009;113(2-3):189-199.
doi:10.1016/j.schres.2009.03.035
53. Gold JM, Barch DM, Feuerstahler LM, et al. Working Memory Impairment Across Psychotic disorders. *Schizophr Bull*. 2019;45(4):804-812. doi:10.1093/schbul/sby134
54. Poldrack RA, Congdon E, Triplett W, et al. A phenome-wide examination of neural and cognitive function. *Sci Data*. 2016;3(1):160110. doi:10.1038/sdata.2016.110

55. Peralta V, Cuesta MJ. Dimensional structure of psychotic symptoms: an item-level analysis of SAPS and SANS symptoms in psychotic disorders. *Schizophr Res.* 1999;38(1):13-26. doi:10.1016/S0920-9964(99)00003-1
56. Leucht S, Samara M, Heres S, Davis JM. Dose Equivalents for Antipsychotic Drugs: The DDD Method: Table 1. *Schizophr Bull.* 2016;42(suppl 1):S90-S94. doi:10.1093/schbul/sbv167
57. Lee J, Green MF, Nuechterlein KH, et al. The effects of age and sex on cognitive impairment in schizophrenia: Findings from the Consortium on the Genetics of Schizophrenia (COGS) study. *PLoS One.* 2020;15(5):e0232855. doi:10.1371/journal.pone.0232855
58. Montejo L, Solé B, Jiménez E, et al. Aging in bipolar disorder: Cognitive performance and clinical factors based on an adulthood-lifespan perspective. *J Affect Disord.* 2022;312:292-302. doi:10.1016/j.jad.2022.06.030
59. Austin SF, Mors O, Budtz-Jørgensen E, et al. Long-term trajectories of positive and negative symptoms in first episode psychosis: A 10year follow-up study in the OPUS cohort. *Schizophr Res.* 2015;168(1-2):84-91. doi:10.1016/j.schres.2015.07.021
60. Kulhara P, Chandiramani K. Positive and negative subtypes of schizophrenia. *Schizophr Res.* 1990;3(2):107-116. doi:10.1016/0920-9964(90)90043-7
61. Mezquida G, Cabrera B, Bioque M, et al. The course of negative symptoms in first-episode schizophrenia and its predictors: A prospective two-year follow-up study. *Schizophr Res.* 2017;189:84-90. doi:10.1016/j.schres.2017.01.047
62. Pogue-Geile MF, Harrow M. Negative Symptoms in Schizophrenia: Their Longitudinal Course and Prognostic Importance. *Schizophr Bull.* 1985;11(3):427-439. doi:10.1093/schbul/11.3.427
63. Patel R, Jayatilleke N, Broadbent M, et al. Negative symptoms in schizophrenia: a study in a large clinical sample of patients using a novel automated method. *BMJ Open.* 2015;5(9):e007619. doi:10.1136/bmjopen-2015-007619
64. Gur RE, Petty RG, Turetsky BI, Gur RC. Schizophrenia throughout life: sex differences in severity and profile of symptoms. *Schizophr Res.* 1996;21(1):1-12. doi:10.1016/0920-9964(96)00023-0
65. Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. *International Review of Psychiatry.* 2010;22(5):417-428. doi:10.3109/09540261.2010.515205
66. Amoretti S, Mezquida G, Verdolini N, et al. Negative symptoms and sex differences in first episode schizophrenia: What's their role in the functional outcome? A longitudinal

- study. *Spanish Journal of Psychiatry and Mental Health*. Published online September 2023. doi:10.1016/j.sjpmh.2023.04.001
67. Leung M.D. DrA, Chue M. R. C. Psych. DrP. Sex differences in schizophrenia, a review of the literature. *Acta Psychiatr Scand*. 2000;101(401):3-38.
doi:10.1111/j.0065-1591.2000.0ap25.x
 68. Maric N, Krabbendam L, Vollebergh W, de Graaf R, van Os J. Sex differences in symptoms of psychosis in a non-selected, general population sample. *Schizophr Res*. 2003;63(1-2):89-95. doi:10.1016/S0920-9964(02)00380-8
 69. Budescu D V. Dominance analysis: A new approach to the problem of relative importance of predictors in multiple regression. *Psychol Bull*. 1993;114(3):542-551.
doi:10.1037/0033-2909.114.3.542
 70. Barrett SL, Kelly C, Bell R, King DJ. Gender influences the detection of spatial working memory deficits in bipolar disorder. *Bipolar Disord*. 2008;10(5):647-654.
doi:10.1111/j.1399-5618.2008.00592.x
 71. Leger M, Neill JC. A systematic review comparing sex differences in cognitive function in schizophrenia and in rodent models for schizophrenia, implications for improved therapeutic strategies. *Neurosci Biobehav Rev*. 2016;68:979-1000.
doi:10.1016/j.neubiorev.2016.06.029
 72. Zhang B, Han M, Tan S, et al. Gender differences measured by the MATRICS consensus cognitive battery in chronic schizophrenia patients. *Sci Rep*. 2017;7(1):11821. doi:10.1038/s41598-017-12027-w
 73. Lecardeur L, Mendrek A, Stip E. Sexual dimorphism of spatial working memory profiles in schizophrenia. *Cogn Neuropsychiatry*. 2010;15(4):397-405.
doi:10.1080/13546800903399183
 74. Solé B, Varo C, Torrent C, et al. Sex differences in neurocognitive and psychosocial functioning in bipolar disorder. *J Affect Disord*. 2022;296:208-215.
doi:10.1016/j.jad.2021.09.066
 75. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J R Stat Soc Series B Stat Methodol*. 1995;57(1):289-300. doi:10.1111/j.2517-6161.1995.tb02031.x
 76. Nieuwenstein MR, Aleman A, de Haan EHF. Relationship between symptom dimensions and neurocognitive functioning in schizophrenia: a meta-analysis of WCST and CPT studies. *J Psychiatr Res*. 2001;35(2):119-125. doi:10.1016/S0022-3956(01)00014-0

77. Ventura J, Thames AD, Wood RC, Guzik LH, Helleman GS. Disorganization and reality distortion in schizophrenia: A meta-analysis of the relationship between positive symptoms and neurocognitive deficits. *Schizophr Res*. 2010;121(1-3):1-14.
doi:10.1016/j.schres.2010.05.033
78. Liddle PF. The Symptoms of Chronic Schizophrenia. *British Journal of Psychiatry*. 1987;151(2):145-151. doi:10.1192/bjp.151.2.145
79. Fleischhacker W, Galderisi S, Laszlovszky I, et al. The efficacy of cariprazine in negative symptoms of schizophrenia: Post hoc analyses of PANSS individual items and PANSS-derived factors. *European Psychiatry*. 2019;58:1-9.
doi:10.1016/j.eurpsy.2019.01.015
80. Krynicki CR, Upthegrove R, Deakin JFW, Barnes TRE. The relationship between negative symptoms and depression in schizophrenia: a systematic review. *Acta Psychiatr Scand*. 2018;137(5):380-390. doi:10.1111/acps.12873
81. Kulhara P, Avasthi A, Chadda R, et al. Negative and Depressive Symptoms in Schizophrenia. *British Journal of Psychiatry*. 1989;154(2):207-211.
doi:10.1192/bjp.154.2.207
82. Kelley ME, van Kammen DP, Allen DN. Empirical Validation of Primary Negative Symptoms: Independence From Effects of Medication and Psychosis. *American Journal of Psychiatry*. 1999;156(3):406-411. doi:10.1176/ajp.156.3.406
83. Carvalho AF, Bortolato B, Miskowiak K, Vieta E, Köhler C. Cognitive dysfunction in bipolar disorder and schizophrenia: a systematic review of meta-analyses. *Neuropsychiatr Dis Treat*. Published online December 2015:3111.
doi:10.2147/NDT.S76700
84. Zakic Milas D, Milas G. WORKING MEMORY IN PATIENTS WITH SCHIZOPHRENIA AND BIPOLAR AFFECTIVE DISORDER: QUANTITATIVE OR QUALITATIVE DIFFERENCES? *Psychiatr Danub*. 2019;31(1):54-61.
doi:10.24869/psyd.2019.54
85. Raffard S, Gutierrez LA, Yazbek H, et al. Working Memory Deficit as a Risk Factor for Severe Apathy in Schizophrenia: A 1-Year Longitudinal Study. *Schizophr Bull*. 2016;42(3):642-651. doi:10.1093/schbul/sbw002
86. Hill SK, Reilly JL, Keefe RSE, et al. Neuropsychological Impairments in Schizophrenia and Psychotic Bipolar Disorder: Findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) Study. *American Journal of Psychiatry*. 2013;170(11):1275-1284. doi:10.1176/appi.ajp.2013.12101298

87. Heinz A, Knable MB, Coppola R, et al. Psychomotor slowing, negative symptoms and dopamine receptor availability—an IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients. *Schizophr Res.* 1998;31(1):19-26. doi:10.1016/S0920-9964(98)00003-6
88. Schultz SK, Miller DD, Oliver SE, Arndt S, Flaum M, Andreasen NC. The life course of schizophrenia: age and symptom dimensions. *Schizophr Res.* 1997;23(1):15-23. doi:10.1016/S0920-9964(96)00087-4
89. Muralidharan A, Harvey PD, Bowie CR. Associations of Age and Gender with Negative Symptom Factors and Functioning Among Middle-Aged and Older Adults with Schizophrenia. *The American Journal of Geriatric Psychiatry.* 2018;26(12):1215-1219. doi:10.1016/j.jagp.2018.07.006
90. Roesch-Ely D, Hornberger E, Weiland S, et al. Do sex differences affect prefrontal cortex associated cognition in schizophrenia? *Schizophr Res.* 2009;107(2-3):255-261. doi:10.1016/j.schres.2008.09.021
91. Minor K, Park S. Spatial working memory: absence of gender differences in schizophrenia patients and healthy control subjects. *Biol Psychiatry.* 1999;46(7):1003-1005. doi:10.1016/S0006-3223(99)00149-3
92. Torniainen M, Suvisaari J, Partonen T, et al. Sex differences in cognition among persons with schizophrenia and healthy first-degree relatives. *Psychiatry Res.* 2011;188(1):7-12. doi:10.1016/j.psychres.2010.11.009

TABLES

Table 1. Demographic and clinical data

	SSD (N=50)	BD-I (N=49)	Test-statistic
Age (years)	36.46 ± 8.878	35.61 ± 9.140	F = .128 (p = .880)
Sex (male / female)	38 / 12	28 / 21	$\chi^2 = 3,960$ (p = 0.047)
Ethnic group			
American Indian or Alaskan Native	11 (22%)	4 (8.2%)	
Asian	1 (2%)	/	
Black/African American	2 (4%)	1 (2%)	
White	33 (66%)	37 (75.5%)	
More than one race	1 (2%)	7 (14.3%)	
SANS			
Apathy-Avolition	2.72 ± 1.512	1.85 ± 1.382	
Anhedonia-Asociality	2.28 ± 1.499	1.70 ± 1.245	
Alogia	.98 ± 1.152	.15 ± .420	
Blunted affect	1.26 ± 1.306	.57 ± 1.088	
Amotivation	5.00 ± 2.770	3.54 ± 2.287	
Diminished expression	2.24 ± 2.246	.72 ± 1.393	
SAPS			
Positive symptoms	4.84 ± 2.795	.72 ± 0.98	F = 44.443 (p = .000)
Disorganization	2.56 ± 2.28	1.63 ± 1.77	F = 2.911 (p = .059)
HAMD-21	11.92 ± 9.001	13.72 ± 9.75	F = 3.765 (p = .027)
Risperidone equivalent dose (mg/d)	7.48 ± 8.79	4.85 ± 10.93	F = 1.41 (p = 0.25)
Patients with mood stabilizer intake	11 (22%)	30 (61%)	$\chi^2 = 15,69$ (p < 0.001)

SSD, schizophrenia spectrum disorder; BD-I, bipolar disorder I; Test-statistic, ANCOVA (sex as covariate); SANS, Scale for the assessment of negative symptoms. SANS amotivation includes the SANS domains avolition-apathy and anhedonia/asociality. SANS diminished expression includes the SANS domains alogia and blunted affect. SAPS, Scale for the assessment of positive symptoms. SAPS positive symptoms includes the SAPS domains delusion and hallucination. SAPS disorganization includes the SAPS domains bizarre behavior and positive formal thought disorder; HAMD-21, Hamilton Depression Scale (21 items)

Table 2. Relationship between negative symptoms domains and other clinical factors

	Beta [95% CI]			
	Avolition-Apathy	Anhedonia-Asociality	Alogia	Blunted affect
Model fit	$r^2_{adj} = .19$ F(5,91) = 5.53***	$r^2_{adj} = .26$ F(5,90) = 7.66***	$r^2_{adj} = .14$ F(5,91) = 4.26*	$r^2_{adj} = .13$ F(5,91) = 3.80*
Group	-0.52 [-1.37 – 0.29]	-0.58 [-1.32 – 0.16]	-0.74[-1.28 - -0.19]**	-0.53 [-1.24 – 0.18]
Positive Symptoms	0.007 [-0.14 – 0.16]	-0.03 [-0.16 – 0.10]	0.004[-0.09 – 0.10]	0.03 [-0.01 – 0.16]
Disorganization	0.25[0.11 – 0.40]***	0.20 [0.07 – 0.34]**	0.04[-0.06 – 0.13]	0.008 [-0.12 – 0.13]
Depression	0.02 [-0.012 – 0.05]	0.05 [0.03 – 0.08]***	0.001[-0.02 – 0.02]	0.02[-0.003 – 0.05]
RSP-eq dose	0.02 [-0.01 – 0.05]	0.01 [-0.01 – 0.04]	0.008[-0.01 – 0.03]	0.03[0.004 – 0.05]*

*Linear multivariate regressions of 4 negative symptom domains as dependent variables with potential sources of negative symptoms as independent variables across SSD and BD-I patients. Beta values and corresponding 95% confidence intervals are given; Positive symptoms were measured using the Scale for the assessment of positive symptoms (SAPS); Depressive symptoms were measured using the Hamilton Depression Scale (21 items); RSP-eq dose, daily antipsychotic dose as risperidone equivalent; * $p < 0.05$ ** $p < 0.005$ *** $p < 0.001$. Statistically significant results after correction for multiple testing (Benjamini-Hochberger procedure, false discovery rate 5%) are bolded.*

Table 3: Model fit and negative symptom dimensions scores and potential sources of secondary negative symptoms all over schizophrenia spectrum and bipolar disorder

	Beta [95% CI]	
	<i>Amotivation</i>	<i>Diminished expression</i>
Model fit	$r^2_{\text{adj}} = .28$ F(5,90) = 8.30***	$r^2_{\text{adj}} = .15$ F(5,91) = 4.35**
Group	-1.14 [-2.5 – 0.22]	-1.27* [-2.40 - -0.13]
Positive Symptoms	-0.020[-0.27 – 0.23]	0.03 [-0.17 – 0.24]
Disorganization	0.47[0.22 – 0.71]***	0.04[-0.16 – 0.25]
Depression	0.07[0.02 – 0.13]**	0.03 [-0.02 – 0.07]
RSP-eq dose	0.03[-0.01 – 0.08]	0.04[-0.002 – 0.08]

*Linear multivariate regressions of the two negative symptom dimensions as dependent variables with potential sources of secondary negative symptoms as independent variables for SSD and BD-I patients independently. Beta values and corresponding 95% confidence intervals are given; Positive symptoms were measured using the Scale for the assessment of positive symptoms (SAPS); Depressive symptoms were measured using the Hamilton Depression Scale (21 items); RSP-eq dose, daily antipsychotic dose as risperidone equivalent; * $p < 0.05$ ** $p < 0.005$ *** $p < 0.001$. Statistically significant results after correction for multiple testing (Benjamini-Hochberg procedure, false discovery rate 5%) are bolded.*

Table 4. Relationship between clinical variables and working memory

	Transdiagnostic	SSD	BD-I
Model fit	$r^2_{\text{adj}} = .27$ $F(9,86) = 4.93^{***}$	$r^2_{\text{adj}} = -.02$ $F(8,41) = 0.85$	$r^2_{\text{adj}} = .27$ $F(8,37) = 3.09^{**}$
Group	2.77[1.14 – 4.40]**	/	/
Avolition-Apathy	-0.74[-1.22 - -0.27]**	-0.58[-1.38 – 0.23]	-1.07[-1.63 – -0.50]***
Anhedonia-Asociality	0.46[-0.1 – 1.03]	0.01[-0.82 – 0.85]	1.32[0.40 – 2.24]**
Alogia	-0.40[-1.19 – 0.39]	-0.47[-1.47 – 0.54]	1.10[-1.9 – 4.08]
Blunted affect	-0.05[-0.65 – 0.55]	0.03[-0.87 – 0.92]	-0.55[-1.68 – 0.58]
Positive symptoms	0.17[-0.11 – 0.46]	0.12[-0.23 – 0.46]	0.61[-0.26 – 1.47]
Disorganization	-0.018 [-0.32 – 0.28]	0.11[-0.33 – 0.55]	-0.12[-0.59 – 0.35]
Depression	-0.007[-0.07 – 0.06]	0.03[-0.08 – 0.14]	-0.10[-0.20 – 0.002]
RSP-eq dose	-0.023[-0.08 – 0.03]	0.03[-0.07 – 0.126]	-0.04[-0.12 – 0.03]

*Linear regressions of negative symptom domains and other clinical variables as independent variables and working memory sum score as dependent variable across SSD and BD-I patients. Beta values and corresponding 95% confidence intervals are given; Positive symptoms were measured using Scale for the assessment of positive symptoms (SAPS); depressive symptoms were measured using Hamilton Depression Scale (21 items); RSP-eq dose, daily antipsychotic dose as risperidone equivalent; * $p < 0.05$ ** $p < 0.005$ *** $p < 0.001$. Statistically significant results after correction for multiple testing (Benjamini-Hochberg procedure, false discovery rate 5%) are bolded. Correction for multiple testing was not applied to SSD and BD-I subgroups.*